Skip to main content

Moderna’s COVID-19 vaccine sales in the third quarter disappoint investors, and its stock takes a hit

It appears that Pfizer has taken the lead in the tug of war for market share among the leading COVID-19 vaccine makers, and Moderna's investors aren't happy about it.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.